Bankruptcy Court OKs Correlogic Motion to 'Reject' Quest, LabCorp Pacts

Correlogic had asked the court to reject agreements it had with Quest and LabCorp as part of its Chapter 11 bankruptcy protection, saying confusion over whether the deals covered Correlogic's ovarian cancer test in its immunoassay format made it challenging for the company to attract investors.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.